187 related articles for article (PubMed ID: 32796449)
1. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy.
Gains JE; Aldridge MD; Mattoli MV; Bomanji JB; Biassoni L; Shankar A; Gaze MN
Nucl Med Commun; 2020 Nov; 41(11):1169-1177. PubMed ID: 32796449
[TBL] [Abstract][Full Text] [Related]
2. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine.
Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):865-73. PubMed ID: 21279352
[TBL] [Abstract][Full Text] [Related]
3.
AlSadi R; Maaz AUR; Bouhali O; Djekidel M
J Nucl Med Technol; 2023 Jun; 51(2):140-146. PubMed ID: 37192823
[No Abstract] [Full Text] [Related]
4. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
5. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P
Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885
[TBL] [Abstract][Full Text] [Related]
6. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
[TBL] [Abstract][Full Text] [Related]
7. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
[TBL] [Abstract][Full Text] [Related]
9. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
10.
Maaz AUR; O'Doherty J; Djekidel M
J Nucl Med Technol; 2021 Sep; 49(3):265-268. PubMed ID: 33820858
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
[TBL] [Abstract][Full Text] [Related]
12. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma.
Gains JE; Bomanji JB; Fersht NL; Sullivan T; D'Souza D; Sullivan KP; Aldridge M; Waddington W; Gaze MN
J Nucl Med; 2011 Jul; 52(7):1041-7. PubMed ID: 21680680
[TBL] [Abstract][Full Text] [Related]
13. [
Samim A; Blom T; Poot AJ; Windhorst AD; Fiocco M; Tolboom N; Braat AJAT; Viol SLM; van Rooij R; van Noesel MM; Lam MGEH; Tytgat GAM; de Keizer B
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1146-1157. PubMed ID: 36504277
[TBL] [Abstract][Full Text] [Related]
14.
Kroiss AS; Uprimny C; Shulkin BL; Gruber L; Frech A; Url C; Riechelmann H; Sprinzl GM; Thomé C; Treglia G; Kjaer A; Fraedrich G; Virgolini IJ
Nucl Med Biol; 2019 Apr; 71():47-53. PubMed ID: 31152973
[TBL] [Abstract][Full Text] [Related]
15. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
[TBL] [Abstract][Full Text] [Related]
16.
Aboian MS; Huang SY; Hernandez-Pampaloni M; Hawkins RA; VanBrocklin HF; Huh Y; Vo KT; Gustafson WC; Matthay KK; Seo Y
J Nucl Med; 2021 Jan; 62(1):43-47. PubMed ID: 32414950
[TBL] [Abstract][Full Text] [Related]
17. I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma.
Yang J; Codreanu I; Servaes S; Zhuang H
Nucl Med Commun; 2012 Nov; 33(11):1134-7. PubMed ID: 22825037
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue.
Gains JE; Sebire NJ; Moroz V; Wheatley K; Gaze MN
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):402-411. PubMed ID: 29043399
[TBL] [Abstract][Full Text] [Related]
19. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
20. The Complementary Role of 68Ga-DOTATATE PET/CT in Neuroblastoma.
Telli T; Lay Ergün E; Volkan Salanci B; Özgen Kiratli P
Clin Nucl Med; 2020 Apr; 45(4):326-329. PubMed ID: 31977455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
